Retatrutide: Research & Studies

Investigational Status Notice#

Retatrutide (LY3437943) is an investigational compound developed by Eli Lilly and Company. It has not been approved by the FDA or any other regulatory agency. All research information presented here is derived from published preclinical studies and Phase 1-2 clinical trials. Phase 3 clinical trials are currently underway. This information is provided for educational and scientific reference purposes only.

Research Overview#

The published research on retatrutide, while limited compared to approved incretin-based therapies, provides a coherent body of evidence supporting its pharmacological rationale as a first-in-class triple GIP/GLP-1/glucagon receptor agonist. The research program has progressed through preclinical characterization, Phase 1 first-in-human studies, and Phase 2 dose-ranging efficacy trials, with Phase 3 confirmatory trials currently ongoing.

The evidence base for retatrutide consists of three principal published studies, supplemented by conference presentations and the ongoing Phase 3 program. The overall evidence level is assessed as low, reflecting the Phase 2 stage of development: while the available data are encouraging, they involve limited participant numbers, relatively short treatment durations, and have not been confirmed in large-scale Phase 3 trials.

Key Clinical Studies#

Phase 2 Obesity Trial (Jastreboff et al., NEJM 2023)#

Study design: This was a randomized, double-blind, placebo-controlled, parallel-group Phase 2 trial (NCT04881760) evaluating the efficacy and safety of retatrutide for weight management in adults with obesity or overweight with weight-related comorbidities.

Participants: 338 adults were enrolled. Key inclusion criteria included BMI of 30 or greater (obesity) or BMI of 27 or greater with at least one weight-related comorbidity, without type 2 diabetes. Participants were randomized to one of several retatrutide dose groups (1 mg, 4 mg with two escalation schedules, 8 mg with two escalation schedules, or 12 mg) or placebo.

Intervention: Retatrutide was administered as a once-weekly subcutaneous injection for 48 weeks. All dose groups initiated treatment at 0.5 mg weekly, with gradual escalation over 12 or 24 weeks to the target dose. All participants received lifestyle modification counseling (reduced-calorie diet and increased physical activity).

Primary endpoint: Percentage change in body weight from baseline at 24 weeks.

Key results:

• At 48 weeks (the end of treatment), mean percentage body weight reductions were dose-dependent:
  • Placebo: approximately -2.1%
  • 1 mg: approximately -8.7%
  • 4 mg: approximately -17.1% (varying by escalation schedule)
  • 8 mg: approximately -22.1% (varying by escalation schedule)
  • 12 mg: approximately -24.2%
• The 24.2% weight loss at the 12 mg dose was the largest mean weight loss reported for any anti-obesity medication at the time of publication, exceeding the approximately 22.5% achieved with tirzepatide 15 mg at 72 weeks (SURMOUNT-1) and the approximately 16.9% achieved with semaglutide 2.4 mg at 68 weeks (STEP 1), though these cross-trial comparisons are indirect and must be interpreted with caution.
• A high proportion of participants in the higher dose groups achieved clinically meaningful weight loss thresholds: approximately 100% of participants in the 12 mg group lost at least 5% of body weight, and approximately 83% lost at least 15%.
• Weight loss curves had not fully plateaued at 48 weeks in the higher dose groups, suggesting that additional weight loss might be achieved with longer treatment duration.

Safety findings: Gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) were the most commonly reported side effects and were dose-dependent. Most GI events were mild to moderate and occurred during dose escalation. Discontinuation rates due to adverse events were low overall but higher in the 12 mg group. No unexpected safety signals were identified.

Limitations: This was a Phase 2 trial with a relatively small sample size (338 participants). The 48-week treatment duration, while informative, is shorter than the 68-72 week durations used in the Phase 3 trials of tirzepatide and semaglutide. The participant population was predominantly White and from the United States, limiting demographic generalizability. Phase 3 confirmation is required.

Phase 2 Type 2 Diabetes Trial (Rosenstock et al., 2023)#

Study design: Randomized, double-blind, placebo-controlled and active-comparator-controlled Phase 2 trial evaluating retatrutide in adults with type 2 diabetes inadequately controlled on metformin monotherapy.

Participants: Adults with type 2 diabetes, HbA1c between 7.0% and 10.5%, on stable metformin therapy. Participants were randomized to retatrutide (multiple dose arms from 0.5 mg to 12 mg), placebo, or an active comparator (dulaglutide 1.5 mg once weekly).

Intervention: Retatrutide or placebo administered as once-weekly subcutaneous injections for 36 weeks, with dose escalation from 0.5 mg to target doses. Background metformin was continued. The inclusion of a dulaglutide comparator arm provided an internal reference for the GLP-1 agonist component.

Key results:

• Retatrutide produced dose-dependent HbA1c reductions, with the highest doses achieving reductions of approximately 1.5-2.0% from baseline.
• Glycemic reductions were superior to placebo and numerically superior to dulaglutide 1.5 mg at the higher retatrutide doses.
• Significant body weight reductions were observed across dose groups, even in this diabetic population where weight loss with GLP-1 agonists is typically less pronounced than in non-diabetic obesity.
• The net glycemic effect was favorable despite the glucagon receptor agonist component, confirming that the GLP-1 and GIP-mediated insulin stimulation sufficiently counterbalances glucagon-mediated hepatic glucose production.
• An exploratory analysis showed reductions in liver fat content, consistent with the hypothesized role of glucagon receptor activation in promoting hepatic lipid oxidation.

Safety findings: The safety profile was consistent with the obesity trial. GI adverse events were the most common side effects. Hypoglycemia rates were low and consistent with the glucose-dependent mechanism of action. No unexpected safety signals were identified.

Limitations: Phase 2 trial with limited sample size. The active comparator was dulaglutide 1.5 mg, which is not the most potent approved GLP-1 agonist (semaglutide) or the dual agonist (tirzepatide), limiting the strength of comparative conclusions. Treatment duration was 36 weeks.

Preclinical and Phase 1 Characterization (Coskun et al., Molecular Metabolism 2022)#

Study design: Combined preclinical pharmacology characterization and first-in-human Phase 1 randomized, double-blind, placebo-controlled study.

Preclinical findings:

• LY3437943 (retatrutide) demonstrated potent agonist activity at human GIP, GLP-1, and glucagon receptors in cell-based assays.
• In animal models (diet-induced obese mice and diabetic rodent models), retatrutide produced dose-dependent reductions in body weight and improvements in glycemic parameters that exceeded those achieved with single or dual agonists.
• The preclinical data supported the hypothesis that adding glucagon receptor agonism to the GIP/GLP-1 agonist mechanism provides incremental metabolic benefit through increased energy expenditure and hepatic fat oxidation.
• Preclinical pharmacokinetic studies confirmed the extended half-life conferred by the C18 fatty acid modification, supporting once-weekly dosing.

Phase 1 human data:

• First-in-human single ascending dose and multiple ascending dose studies demonstrated acceptable safety and tolerability.
• Pharmacokinetic data confirmed once-weekly dosing feasibility, with a half-life of approximately 6 days.
• Preliminary signals of glucose-lowering and weight reduction were observed even in the short Phase 1 study duration.

Limitations: Phase 1 data involve small participant numbers and short durations, providing only initial safety and pharmacokinetic information. The preclinical findings, while supportive, require clinical validation.

Systematic Reviews and Meta-Analyses#

Given the early stage of retatrutide's clinical development (Phase 2 completed, Phase 3 ongoing), no systematic reviews or meta-analyses dedicated specifically to retatrutide have been published. However, retatrutide has been included in several broader reviews and meta-analyses of incretin-based therapies for obesity and type 2 diabetes:

• Network meta-analyses comparing anti-obesity medications have incorporated retatrutide Phase 2 data alongside Phase 3 data for semaglutide, tirzepatide, and other agents. These analyses generally position retatrutide at the higher end of the efficacy spectrum for weight loss, though with the caveat that Phase 2 data may not directly predict Phase 3 outcomes.

• Reviews of the incretin agonist field have discussed retatrutide as representing the next evolutionary step in multi-receptor targeting, highlighting the theoretical and observed benefits of adding glucagon receptor agonism.

• Narrative reviews of MASLD/NASH therapeutics have noted retatrutide's potential for liver fat reduction based on the Phase 2 exploratory data, positioning it alongside survodutide and other glucagon receptor-containing agonists as candidates for this indication.

Phase 3 Clinical Program#

Eli Lilly has initiated a comprehensive Phase 3 clinical program for retatrutide, though specific trial designs and registrations are subject to change. The Phase 3 program is expected to include:

• Obesity indication: Large-scale, randomized, placebo-controlled trials evaluating retatrutide for chronic weight management in adults with obesity or overweight with comorbidities, with treatment durations of 52-72 weeks or longer.

• Type 2 diabetes indication: Trials evaluating retatrutide as monotherapy or in combination with other antidiabetic agents for glycemic control in type 2 diabetes.

• MASLD/NASH indication: Given the Phase 2 liver fat reduction data and the mechanistic rationale for glucagon receptor-mediated hepatic fat clearance, dedicated trials in MASLD or NASH are anticipated.

• Cardiovascular outcomes: A cardiovascular outcomes trial (CVOT) may be planned or required to demonstrate long-term cardiovascular safety and potentially cardiovascular benefit, following the precedent set by semaglutide's SELECT trial.

Mechanism of Action Research#

The mechanistic rationale for retatrutide's triple agonist approach is supported by both preclinical research and the observed clinical data:

GIP Receptor Agonism#

The GIP receptor backbone of retatrutide provides several metabolic benefits. GIP receptor activation enhances glucose-dependent insulin secretion from pancreatic beta cells, promotes beta-cell survival and proliferation, and may influence lipid metabolism in adipose tissue. The contribution of GIP receptor agonism to obesity treatment was initially uncertain (GIP has complex biology in adipose tissue), but the clinical success of tirzepatide (a GIP/GLP-1 dual agonist) validated the importance of this receptor in multi-target metabolic therapy.

GLP-1 Receptor Agonism#

GLP-1 receptor agonism is the best-characterized component of retatrutide's mechanism. GLP-1 receptor activation produces appetite suppression through central hypothalamic and brainstem signaling, delays gastric emptying (contributing to early satiety), enhances glucose-dependent insulin secretion, suppresses inappropriate glucagon secretion (distinct from the direct glucagon receptor agonism of retatrutide), and may have direct effects on cardiac and renal physiology.

Glucagon Receptor Agonism#

The glucagon receptor component is the defining mechanistic innovation of retatrutide. Glucagon receptor activation increases hepatic glucose production (counterbalanced by the GLP-1/GIP-mediated insulin response), stimulates hepatic fatty acid oxidation and lipid clearance, promotes thermogenesis and increases energy expenditure, and may influence amino acid metabolism and lean body mass preservation. The combined effect of reducing energy intake (via GLP-1/GIP-mediated appetite suppression) while simultaneously increasing energy output (via glucagon-mediated thermogenesis) creates a dual metabolic lever for weight loss that is unique among current anti-obesity therapies.

Evidence Quality Assessment#

The evidence base for retatrutide is assessed as low according to standard evidence quality frameworks:

Strengths of the evidence:

• Published in high-impact, peer-reviewed journals (NEJM, The Lancet, Molecular Metabolism)
• Randomized, double-blind, placebo-controlled study designs
• Consistent dose-response relationships across endpoints
• Results aligned with the mechanistic hypothesis
• Inclusion of an active comparator in the diabetes trial

Limitations of the evidence:

• Phase 2 sample sizes (hundreds, not thousands, of participants)
• Treatment durations of 36-48 weeks (shorter than Phase 3 comparator trials)
• Limited demographic diversity (predominantly White, US-based populations)
• No long-term safety data beyond 48 weeks
• No cardiovascular or mortality outcomes data
• No head-to-head comparisons with tirzepatide or high-dose semaglutide
• Phase 2 efficacy results may not fully predict Phase 3 outcomes

Research Gaps and Future Directions#

The following research gaps are identified as priorities for the retatrutide clinical development program and the broader scientific community:

1. Phase 3 completion and analysis: The most critical evidence gap is the completion and publication of Phase 3 trials, which will provide the large-scale efficacy and safety data needed for regulatory submission and clinical decision-making.

2. Long-term safety: Extension studies and long-term follow-up beyond 48 weeks are essential to characterize the durability of weight loss, the safety profile with prolonged use, and the effects of treatment discontinuation (weight regain patterns).

3. Cardiovascular outcomes: A dedicated cardiovascular outcomes trial is needed to establish whether retatrutide, like semaglutide, provides cardiovascular benefit or is at minimum cardiovascularly safe.

4. MASLD/NASH dedicated trials: The Phase 2 liver fat reduction data support dedicated trials in metabolic liver disease, with histological endpoints (liver biopsy) to assess effects on steatohepatitis, fibrosis, and disease progression.

5. Head-to-head comparisons: Direct comparative trials against tirzepatide and/or semaglutide would provide the most informative efficacy and safety comparisons, eliminating the limitations of indirect cross-trial comparisons.

6. Body composition analysis: Detailed assessment of the effects of retatrutide on fat mass versus lean body mass, using methods such as DEXA scanning, is needed to understand whether the glucagon component favorably influences body composition during weight loss.

7. Special populations: Studies in pediatric and adolescent patients, elderly patients, patients with renal or hepatic impairment, and ethnically diverse populations are needed to establish the generalizability of efficacy and safety.

8. Combination therapy: Exploration of retatrutide in combination with other weight management strategies (behavioral interventions, other pharmacotherapies, bariatric surgery adjunct) may identify optimal treatment algorithms.

9. Mechanism elucidation: Further research into the relative contributions of each receptor component (GIP, GLP-1, glucagon) to the observed clinical effects, including studies with selective receptor antagonists or single/dual comparators, would advance understanding of the triple agonist mechanism.

10. Weight maintenance: Studies of dose reduction or treatment discontinuation strategies, including the pattern and magnitude of weight regain after stopping retatrutide, are important for long-term clinical management planning.

Until Phase 3 data are available, all conclusions about retatrutide's efficacy, safety, and clinical utility must be considered preliminary. The compound remains investigational and is not available for clinical use outside of authorized clinical trials.

Related Reading#

• Retatrutide overview and research guide
• Retatrutide dosing protocols
• Retatrutide molecular structure